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OBJECTIVE: To estimate cost-effectiveness of pathogen
inactivation for platelet transfusions in Dutch cardiac
surgery. We used decision-tree analysis to evaluate the
cost-effectiveness of the addition of pathogen inactivation
of pooled platelets to standard procedures for platelet
transfusion safety (such as, donor recruitment and screen-
ing). METHODS: Data on transfusions were derived
from the University Hospital Groningen (Netherlands)
for 1997. Characteristics of platelet recipients (age,
gender, survival) and data/assumptions on viral and bac-
terial risks were linked to direct and indirect costs/bene-
ﬁts of pathogen inactivation. Post-transfusion survival
was simulated with a Markov-model. Standard methods
for cost-effectiveness were used. Cost-effectiveness was
expressed in net costs per life-year gained and estimated
in baseline-, sensitivity- and scenario analysis. Sensitivity
was analysed with respect to viral risks, discard rate and
discounting. Stochastic sensitivity analysis was performed
on bacterial risks. Scenario analysis was elaborated on
judicial aspects and occurrence of a new yet unknown
virus. RESULTS: Net costs per life-year gained were
€110,000 in the baseline (90% CI: €80,000–€180,000).
Sensitivity analysis revealed that cost-effectiveness was
insensitive to viral risks, but highly sensitive to, for
example, the assumed reduction in the discard rate and
discounting of life-years gained. Sensitivity and scenario
analysis showed potential reductions in cost-effectiveness
down to €50,000 per life-year gained. CONCLUSIONS:
Given relatively high net costs per life-year gained that
are internationally accepted for blood transfusion safety
interventions, our estimated cost-effectiveness ﬁgures for
pathogen inactivation may reﬂect acceptable cost-
effectiveness in this speciﬁc area. Validation of several
crucial parameters is required, in particular the Dutch risk
for acquiring transfusion-related sepsis. Further work
should extend the model to other countries, other patient
groups (haematology) and the potential elimination of
donor testing if pathogen inactivation is to cover the
whole spectra of pathogens and blood products.
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COSTS OF STROKE:A COMPARISON OF
REGULAR CARE AND THREE EXPERIMENTAL
STROKE SERVICES IN THE NETHERLANDS
Van Exel J, Koopmanschap M
Erasmus University, Rotterdam, Netherlands
OBJECTIVES: Determine patient costs after stroke and
compare costs between regular care for stroke patients
and care organised in stroke services. METHODS:
Patient costs after stroke were calculated within the
framework of the evaluation of three experiments with
stroke services in the Netherlands. Total costs of care per
patient for the 6-month follow up were based on medical
consumption of 598 patients in 6 regions consecutively
admitted to a hospital after stroke. Care consumption and
cost data were collected for hospital, rehabilitation,
nursing home, and home care. Care consumption was
retrieved from patients’ medical records and from patient
interviews two and six months after stroke. Unit cost data
were collected at participating institutions. RESULTS: We
found that the total costs of care per patient for the 6
month follow up after stroke amount to almost €16,000
on average. Costs are dominated by institutional costs
and accommodation costs. Patients who die during the
acute phase incur less costs. For patients that survive the
acute phase, severity of disability, age, gender and place
of residence before stroke are the most important deter-
minants of costs, as they inﬂuence patients’ stroke careers.
These determinants of costs also interact. CONCLU-
SIONS: Stroke care organised in stroke service experi-
ments potentially is more effective than regular care,
although large differences in costs were found between
the three stroke services. The most efﬁcient stroke service
experiment was the one that was most successful in co-
ordinating patient ﬂow from hospital to (nursing) home,
through capacity planning and efﬁcient discharge proce-
dures. The other experiments suffered from waiting lists
for (nursing) home care, leading to “blocked beds” and
higher costs of care. The relations found between costs,
organisation of care, patient characteristics and disease
severity may be applied as building-blocks for DRGs for
stroke care.
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OBESITY AND POTENTIAL COST OFFSETS
FROM WEIGHT LOSS—FINDINGS FROM THE
SWEDISH MALMO PREVENTION STUDY
Persson U1, Odegaard K1, Nilsson JA2, Nilsson P2,
Berglund G2
1IHE, Lund, Sweden; 2University Hospital, Malmo, Sweden
OBJECTIVE: The study aims to 1) estimate the costs of
hospital treatmetn and the value of lost production due
to early death associated with underweight, overweight
and obese patients, and to extrapolate the ﬁndings to
national costs and 2) estimate the potential beneﬁts of an
obesity intervention program in terms of cost-offsets.
METHODS: For the ﬁrst aim we use a retrospective
analysis of the hospital treatment episodes of a deﬁned
population with data obtained from screening of 33,196
middle-aged subjects living in Malmo, Sweden and col-
lected during a 15-year follow-up period. For the second
aim we apply a prospective cost analysis within a model-
ing framework. RESULTS: The yearly excess hospital
(somatic, psychiatric) care cost (SEK) for overweight (25-
BMI-29kg/sqm) and obesity (BMI 30kg/sqm and above)
was estimated to SEK 1300 million (US$130 million,
assuming $1 = SEK10), or about 2.3 percent of total hos-
pital care costs in Sweden. Indirect costs due to early mor-
tality for obese subjects were estimated to SEK 1200
million (US$120 million). For males at age 55+ the poten-
tial hospital costs savings, excluding costs of intervention,
that could be gained by an intervention that successfully
and sefely could alter the weight of an overweight or
obese individual to become normal weight was estimated
to SEK 30,000 (US$3,000) over 15 years. CONCLU-
SION: Hospital treatment costs are found to have a J-
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shaped relationship to weight (BMI) indicating potential
cost offsets by effective weight-loss intervention.
CARDIOVASULAR DISEASES/DISORDERS—
Clinical Outcomes
PCV37
DOES COMPLIANCE WITH ACE-I, DIGOXIN AND
SPIRONOLACTONE INFLUENCE THE TIME TO
EVENT IN PATIENTS WITH HEART FAILURE?
Gwadry-Sridhar F1,Arnold M2,Weaver B1, Guyatt G1
1McMaster University, London, ON, Canada; 2London Health
Sciences Centre, London, ON, Canada
OBJECTIVES: Patients with Heart Failure (HF) are
known to have poor compliance even with medications
that can help reduce mortality and events such as 
readmissions. We wanted to examine whether compliance
with three such medications, primarily ACE-Inhibitors,
Digoxin and Spironolactone would have any impact on
the time to an event in HF patients. An event was deﬁned
as a readmission to hospital, an emergency room visit fol-
lowing a discharge from the index admission or death.
METHODS: Patients with HF who were admitted to the
London Health Sciences Centre were stratiﬁed then ran-
domized to receive either usual care education (U) or an
enhanced educational intervention (I) aimed at improving
compliance that was delivered in hospital, prior to dis-
charge. Compliance data was collected from pharmacy
reﬁll data from baseline over the period of follow-up that
was 12 months. A Cox Regression time-to-event analysis
was run for all patients adjusting for randomization ARM
and then adjusting for the covariates of interest, the
minimum and mean compliance. RESULTS: Seventy-ﬁve
out of 134 patients had an event. There was no difference
in time to event by ARM. The inclusion of the minimum
and mean compliance of each drug individually in the
regression did not result in any signiﬁcant changes in the
time-to-event; however, there was a trend p = 0.082 in
patients who were on spironolactone and had compliance
<0.80. CONCLUSIONS: We can hypothesize that there
may be a differential effect on the time to an event in this
population depending upon the medication. We should be
careful not to group all medication compliance into one
composite number as different medications in HF have
different effects on survival. This data warrants a more
careful assessment of compliance for each HF medication
and a determination of its effect on clinical outcomes of
interest.
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LIPID LOWERING MEDICATIONS 
FOLLOWING CORONARY
REVASCULARIZATION PROCEDURES
Brophy J, Bourgault C, Brassard P
McGill University, Montreal, QC, Canada
OBJECTIVES: Clinical trials have demonstrated
improved outcomes in patients receiving cholesterol low-
ering medications (CLM) following coronary revascu-
larization and clinical guidelines recommend aggressive
cholesterol lowering therapy for patients with established
coronary disease. However, in routine practice, the degree
to which these recommendations are followed and their
impact are unknown. METHODS: Using administrative
databases, we examined the use of CLM in a consecutive
cohort of 11,985 elderly (average age 71.4) patients
undergoing coronary revascularization from 1995 until
1997 in Quebec, Canada. RESULTS: Before revascular-
ization, 30.9% were receiving CLM. After a 3-year
follow-up, 62.8% of cohort survivors had received at
least 1 prescription for CLM. CABG patients had a
decreased probability of receiving CLM compared to PCI
patients (OR .75 95% CI .72–.79). High-risk patients
especially the very elderly (>75) had a signiﬁcantly
decreased probability of receiving CLM (OR .61 95% CI
.57–.66). The most potent predictor of a post-operative
prescription use was pre-operative utilization (OR 7.1
95% CI 6.8–7.5). An adjusted time-dependent analysis
showed that patients receiving CLM had a lower risk of
death (RR 0.61 95% CI 0.52–0.79) or myocardial infarc-
tion (RR 0.78 95% CI 0.64–0.93) than those not exposed
to these drugs. There was no difference in the need for a
repeat revascularization between the groups (RR 1.05
95% CI 0.91–1.20). CONCLUSIONS: CLM were under-
used in this post revascularization population and this
underuse was associated with an increase in adverse 
outcomes.
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A REVIEW OF THE PHARMACOTHERAPEUTIC
MANAGEMENT OF PULMONARY 
ARTERIAL HYPERTENSION
Richard LJ, Howard PA,Thorpe T
Heron Evidence Development LTD, Stevenage,
United Kingdom
Pulmonary arterial hypertension (PAH) is a rare, incur-
able and often fatal disorder of the lung in which pul-
monary artery pressure rises to abnormal levels. It may
either be idiopathic in nature (primary pulmonary hyper-
tension) or a manifestation of many different disorders
(secondary pulmonary hypertension). Current manage-
ment includes prostacyclin vasodilator therapy, and con-
ventional therapy consisting of calcium channel blockers,
anticoagulation, oxygen therapy and diueresis; and newer
agents such as bosentan, an endothelin antagonist. To
date, no systematic review has assessed these interven-
tions. OBJECTIVES: To perform a systematic review of
the medical interventions used in the management of
PAH. METHODS: A literature search of EMBASE and
MEDLINE was performed, and studies matching the pre-
deﬁned inclusion criteria extracted to HTA-standardised
grids and graded using the Jadad score. Data for three
outcome measures survival, exercise capacity and right
